Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The International Journal of Risk & Safety in Medicine: Past and future.

The International journal of risk & safety in medicine·2023
Same author

Risk and benefit issues are problems we all face.

The International journal of risk & safety in medicine·2022
Same author

Wiser after the event?

The International journal of risk & safety in medicine·2022
Same author

Future possibilities for The International Journal of Risk and Safety in Medicine.

The International journal of risk & safety in medicine·2021
Same author

What is fake news in science?

The International journal of risk & safety in medicine·2021
Same author

What is 'risk and safety in medicine'?

The International journal of risk & safety in medicine·2021
Same journal

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

British journal of clinical pharmacology·2026
Same journal

Comparative risk of ventricular arrhythmia and sudden cardiac death among acetylcholinesterase inhibitors in dementia: A population-based cohort study.

British journal of clinical pharmacology·2026
Same journal

Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus.

British journal of clinical pharmacology·2026
Same journal

Impact of cumulative glucocorticoid exposure on vancomycin clearance in hospitalized children: A retrospective cohort study.

British journal of clinical pharmacology·2026
Same journal

Development of a population pharmacokinetic model using combined paediatric and adult data for four pulmonary arterial hypertension drugs.

British journal of clinical pharmacology·2026
Same journal

Case-malformed signal detection and prioritisation using EUROmediCAT data for pharmacovigilance in pregnancy.

British journal of clinical pharmacology·2026
See all related articles

Related Experiment Video

Updated: May 24, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Pharmacovigilance.

I Ralph Edwards1

  • 1Uppsala Monitoring Centre, Uppsala, Sweden. Ralph.Edwards@who-umc.org

British Journal of Clinical Pharmacology
|February 25, 2012
PubMed
Summary
This summary is machine-generated.

Adverse drug reactions are a significant public health issue. Improving pharmacovigilance requires clearer objectives, better data methods, and enhanced communication for patient safety.

More Related Videos

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

Related Experiment Videos

Last Updated: May 24, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

Area of Science:

  • Pharmacovigilance and Drug Safety
  • Public Health

Background:

  • Adverse drug reactions (ADRs) represent a major global health concern, ranking as the fifth leading cause of mortality in developed nations.
  • Current pharmacovigilance practices lack clear objectives, standardized protocols, and robust decision-making frameworks, hindering effective ADR management.

Purpose of the Study:

  • To identify critical limitations in current pharmacovigilance systems.
  • To propose essential areas for development to enhance the detection, assessment, and management of adverse drug reactions.

Main Methods:

  • Analysis of existing pharmacovigilance processes, highlighting issues such as under-reporting, poor data quality, and inadequate causality assessment.
  • Identification of key areas for improvement, including data management, secondary effect recognition, and interaction analysis.

Main Results:

  • Significant challenges exist in pharmacovigilance, including under-reporting, suboptimal use of technology, and poor causality assessment, impeding effective risk management.
  • Essential advancements are needed in pharmacoepidemiology, data mining for knowledge discovery, and communication technologies.

Conclusions:

  • A rigorous, documented, and publicly reviewed approach to pharmacovigilance is crucial for improving public health safety.
  • Incorporating patient perspectives on benefit/harm perceptions is vital for setting appropriate regulatory and pharmacovigilance targets.